David Graham

List of Publications by Year in descending order

315 papers	29,926 citations	9264 74 h-index	5394 164 g-index
326 all docs	326 docs citations	326 times ranked	17327 citing authors

#	Article	IF	Citations
1	Management ofHelicobacter pyloriinfectionâ€"the Maastricht V/Florence Consensus Report. Gut, 2017, 66, 6-30.	12.1	2,245
2	Management ofHelicobacter pyloriinfectionâ€"the Maastricht IV/ Florence Consensus Report. Gut, 2012, 61, 646-664.	12.1	2,023
3	Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 2017, 153, 420-429.	1.3	1,983
4	Kyoto global consensus report onHelicobacter pylorigastritis. Gut, 2015, 64, 1353-1367.	12.1	1,256
5	Replication of human noroviruses in stem cellâ€"derived human enteroids. Science, 2016, 353, 1387-1393.	12.6	1,056
6	Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 2010, 59, 1143-1153.	12.1	821
7	Prevalence of Antibiotic Resistance in Helicobacter pylori: AÂSystematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology, 2018, 155, 1372-1382.e17.	1.3	740
8	Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 150, 1113-1124.e5.	1.3	682
9	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England Journal of Medicine, 2016, 375, 2519-2529.	27.0	607
10	PREVENTION OF NSAID-INDUCED GASTRIC ULCER WITH MISOPROSTOL: MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Lancet, The, 1988, 332, 1277-1280.	13.7	549
11	Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology, 1992, 102, 493-496.	1.3	541
12	Visible small-intestinal mucosal injury in chronic NSAID users. Clinical Gastroenterology and Hepatology, 2005, 3, 55-59.	4.4	512
13	Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 1996, 40, 477-480.	3.2	497
14	Gastritis staging in clinical practice: the OLGA staging system. Gut, 2007, 56, 631-636.	12.1	370
15	British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut, 2019, 68, 1545-1575.	12.1	365
16	Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology, 2015, 148, 719-731.e3.	1.3	346
17	A Report Card to Grade Helicobacter pylori Therapy. Helicobacter, 2007, 12, 275-278.	3.5	327
18	Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model. Gastroenterology, 1997, 113, 1983-1991.	1.3	309

#	Article	IF	Citations
19	Antibiotic resistance in : Implications for therapy. Gastroenterology, 1998, 115, 1272-1277.	1.3	298
20	New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 321-331.	1.7	298
21	Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology. Journal of Virology, 2016, 90, 43-56.	3.4	298
22	Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence. Clinical Gastroenterology and Hepatology, 2014, 12, 177-186.e3.	4.4	290
23	Changing Trends in Stomach Cancer Throughout the World. Current Gastroenterology Reports, 2017, 19, 36.	2.5	281
24	Removal of small colorectal polyps in anticoagulated patients: aÂprospective randomized comparison of cold snare and conventional polypectomy. Gastrointestinal Endoscopy, 2014, 79, 417-423.	1.0	264
25	OLGA staging for gastritis: A tutorial. Digestive and Liver Disease, 2008, 40, 650-658.	0.9	258
26	Treatment of Helicobacter pylori Reduces the Rate of Rebleeding in Peptic Ulcer Disease. Scandinavian Journal of Gastroenterology, 1993, 28, 939-942.	1.5	255
27	History ofHelicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World Journal of Gastroenterology, 2014, 20, 5191.	3.3	245
28	Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut, 2020, 69, 2093-2112.	12.1	239
29	Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Human Pathology, 1996, 27, 35-41.	2.0	237
30	Possible role ofHelicobacter pylori infection in early gastric cancer development. Cancer, 1994, 73, 2691-2694.	4.1	216
31	Cimetidine, Cigarette Smoking, and Recurrence of Duodenal Ulcer. New England Journal of Medicine, 1984, 311, 689-693.	27.0	214
32	Gastric adaptation occurs with aspirin administration in man. Digestive Diseases and Sciences, 1983, 28, 1-6.	2.3	211
33	Effect of Triple Therapy (Antibiotics plus Bismuth) on Duodenal Ulcer Healing. Annals of Internal Medicine, 1991, 115, 266-269.	3.9	208
34	Atrophic Gastritis and Intestinal Metaplasia in Japan: Results of a Large Multicenter Study. Helicobacter, 2001, 6, 294-299.	3.5	197
35	Challenge model for Helicobacter pylori infection in human volunteers. Gut, 2004, 53, 1235-1243.	12.1	197
36	Role of bismuth in improvingHelicobacter pylorieradication with triple therapy. Gut, 2016, 65, 870-878.	12.1	197

#	Article	IF	Citations
37	Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. American Journal of Gastroenterology, 1988, 83, 974-80.	0.4	196
38	Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 2018, 16, 992-1002.e6.	4.4	189
39	Effect of Age on the Frequency of Active Campylobacter pylori Infection Diagnosed by the [13]Urea Breath Test in Normal Subjects and Patients with Peptic Ulcer Disease. Journal of Infectious Diseases, 1988, 157, 777-780.	4.0	165
40	H. pyloriandcagA: Relationships with Gastric Cancer, Duodenal Ulcer, and Reflux Esophagitis and Its Complications. Helicobacter, 1998, 3, 145-151.	3.5	164
41	Gastric Cancer as Preventable Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1833-1843.	4.4	162
42	Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. American Journal of Gastroenterology, 1993, 88, 1860-4.	0.4	150
43	MicroRNA signatures differentiate Crohnâ€™s disease from ulcerative colitis. BMC Immunology, 2015, 16, 5.	2.2	145
44	Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut, 2019, 68, 11-17.	12.1	132
45	Diseaseâ€specific Helicobacter pylori Virulence Factors: The Unfulfilled Promise. Helicobacter, 2000, 5, 3-9.	3.5	129
46	Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-lineHelicobacter pyloritherapy. Gut, 2015, 64, 1715-1720.	12.1	129
47	Prospective, randomized comparison of 2 methods of cold snare polypectomy for small colorectal polyps. Gastrointestinal Endoscopy, 2015, 82, 686-692.	1.0	128
48	Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clinical Gastroenterology and Hepatology, 2015, 13, 1616-1624.	4.4	128
49	How to Effectively Use Bismuth Quadruple Therapy. Gastroenterology Clinics of North America, 2015, 44, 537-563.	2.2	127
50	Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clinical Gastroenterology and Hepatology, 2018, 16, 800-808.e7.	4.4	127
51	Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infectionâ˜†. Gastroenterology, 2004, 126, 1030-1043.	1.3	126
52	Therapy of Helicobacter pylori: current status and issues. Gastroenterology, 2000, 118, S2-S8.	1.3	119
53	Helicobacter pylori infection and antibiotic resistance: a WHO high priority?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 383-384.	17.8	119
54	Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology, 2018, 155, 67-75.	1.3	117

#	Article	IF	Citations
55	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 2009, 157, 606-612.	2.7	115
56	Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut, 2008, 57, 1065-1072.	12.1	113
57	Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection. Gastroenterology Clinics of North America, 2010, 39, 465-480.	2.2	113
58	Serological Correlates of Protection against a GII.4 Norovirus. Vaccine Journal, 2015, 22, 923-929.	3.1	109
59	The time to eradicate gastric cancer is now. Gut, 2005, 54, 735-738.	12.1	108
60	Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut, 1999, 45, 804-811.	12.1	107
61	Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. International Journal of Antimicrobial Agents, 2001, 17, 39-44.	2.5	105
62	Efficient Identification and Evaluation of Effective Helicobacter pylori Therapies. Clinical Gastroenterology and Hepatology, 2009, 7, 145-148.	4.4	105
63	Systematic review with metaâ€analysis: the global recurrence rate of Helicobacter pylori. Alimentary Pharmacology and Therapeutics, 2017, 46, 773-779.	3.7	101
64	Helicobacter pylori management in ASEAN: The Bangkok consensus report. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 37-56.	2.8	100
65	Pretreatment Antibiotic Resistance inHelicobacter pyloriInfection: Results of Three Randomized Controlled Studies. Helicobacter, 1999, 4, 106-112.	3.5	99
66	Helicobacter pyloritherapy: a paradigm shift. Expert Review of Anti-Infective Therapy, 2016, 14, 577-585.	4.4	96
67	Regional Differences in Metronidazole Resistance and Increasing Clarithromycin Resistance among Helicobacter pylori Isolates from Japan. Antimicrobial Agents and Chemotherapy, 2000, 44, 2214-2216.	3.2	95
68	Effect of Fluoroquinolone Resistance on 14â€day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy. Helicobacter, 2013, 18, 373-377.	3.5	94
69	Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut, 2021, 70, gutjnl-2020-322200.	12.1	91
70	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology, 2021, 161, 495-507.e4.	1.3	89
71	Helicobacter pylori Infection Introduces DNA Double-Strand Breaks in Host Cells. Infection and Immunity, 2014, 82, 4182-4189.	2.2	88
72	Double-Blind Comparison of Bismuth Subsalicylate and Placebo in the Prevention and Treatment of Enterotoxigenic Escherichia coli-Induced Diarrhea in Volunteers. Gastroenterology, 1983, 85, 1017-1022.	1.3	87

#	Article	IF	Citations
73	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq1 1 0.784314 rgBT /Overloc 38, 3282-3292.	2.2	86
74	Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. Viruses, 2019, 11, 638.	3.3	84
75	Randomised controlled trial: susceptibilityâ€guided therapy versus empiric bismuth quadruple therapy for firstâ€line Helicobacter pylori treatment. Alimentary Pharmacology and Therapeutics, 2019, 49, 1385-1394.	3.7	79
76	Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology, 2018, 154, 462-466.	1.3	78
77	Dietary quality and the colonic mucosaâ€“associated gut microbiome in humans. American Journal of Clinical Nutrition, 2019, 110, 701-712.	4.7	78
78	Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. Journal of Gastroenterology, 2010, 45, 1-8.	5.1	75
79	Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1700-1710.	7.1	75
80	Serological evidence of SV40 infections in HIV-infected and HIV-negative adults. , 1998, 54, 276-284.		74
81	B-Cell and T-Cell Immune Responses to Experimental Helicobacter pylori Infection in Humans. Infection and Immunity, 2005, 73, 2999-3006.	2.2	74
82	Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. American Journal of Gastroenterology, 2002, 97, 857-860.	0.4	73
83	Chronicles of a cancer foretold: 35â€...years of gastric cancer risk assessment. Gut, 2016, 65, 721-725.	12.1	72
84	An enteric-coated pancreatic enzyme preparation that works. Digestive Diseases and Sciences, 1979, 24, 906-909.	2.3	70
85	Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. The Lancet Gastroenterology and Hepatology, 2018, 3, 698-707.	8.1	69
86	Clarithromycin for the Eradication of Helicobacter Pylori. Journal of Clinical Gastroenterology, 1993, 16, 292-294.	2.2	66
87	African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. Journal of Digestive Diseases, 2009, 10, 77-84.	1.5	66
88	Furazolidone combination therapies for Helicobacter pylori infection in the United States. Alimentary Pharmacology and Therapeutics, 2000, 14, 211-215.	3.7	65
89	Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clinical Pharmacology and Therapeutics, 1985, 38, 65-70.	4.7	64
90	Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Alimentary Pharmacology and Therapeutics, 2000, 14, 745-750.	3.7	64

#	Article	IF	Citations
91	Strategy for Eliminating Gastric Cancer in Japan. Helicobacter, 2010, 15, 486-490.	3.5	64
92	Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistantHelicobacter pyloriATCC43504 and its involvement in metronidazole resistance. FEMS Microbiology Letters, 2000, 188, 197-202.	1.8	63
93	Non-replicating oral whole cell vaccine protective against enterotoxigenicEscherichia coli(ETEC) diarrhea: Stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiology Letters, 1988, 47, 117-125.	1.8	62
94	Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication. Annals of Internal Medicine, 2020, 172, 795-802.	3.9	62
95	Pathogenesis and therapy of gastric and duodenal ulcer disease. Medical Clinics of North America, 2002, 86, 1447-1466.	2.5	61
96	Relative potency of protonâ€pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of doubleâ€dose PPI. Helicobacter, 2019, 24, e12554.	3.5	61
97	Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14â€ƒDays. Helicobacter, 2011, 16, 295-300.	3.5	60
98	Helicobacter pylorias an oncogenic pathogen, revisited. Expert Reviews in Molecular Medicine, 2017, 19, e4.	3.9	60
99	Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. Gut Microbes, 2019, 10, 504-520.	9.8	59
100	In vivo susceptibility of Campylobacter pylori. American Journal of Gastroenterology, 1989, 84, 233-8.	0.4	59
101	Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1997, 11, 935-938.	3.7	58
102	Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. Journal of Gastroenterology, 2010, 45, 816-820.	5.1	58
103	PPIâ€amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and metaâ€analysis. Helicobacter, 2020, 25, e12692.	3.5	58
104	Diagnosis and Treatment of Helicobacter pylori Infection. Annual Review of Medicine, 2022, 73, 183-195.	12.2	58
105	Bismuth-containing quadruple therapy for Helicobacter pylori. European Journal of Gastroenterology and Hepatology, 2013, 25, 1.	1.6	56
106	Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results. Clinical Gastroenterology and Hepatology, 2010, 8, 1032-1036.	4.4	55
107	Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Review of Anti-Infective Therapy, 2018, 16, 679-687.	4.4	55
108	Isolation and Characterization of Tetracycline-Resistant Clinical Isolates of Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 2000, 44, 3203-3205.	3.2	53

#	Article	IF	Citations
109	Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clinical Gastroenterology and Hepatology, 2022, 20, 973-983.e1.	4.4	53
110	Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleveland Clinic Journal of Medicine, 2017, 84, 310-318.	1.3	53
111	Gastroduodenal complications of chronic NSAID therapy. American Journal of Gastroenterology, 1988, 83, 1081-4.	0.4	53
112	Highâ€dose PPIâ€amoxicillin dual therapy with or without bismuth for firstâ€line Helicobacter pylori therapy: A randomized trial. Helicobacter, 2019, 24, e12596.	3.5	52
113	Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology, 1988, 95, 327-33.	1.3	52
114	Mass Eradication of Helicobacter pylori to Prevent Gastric Cancer: Theoretical and Practical Considerations. Gut and Liver, 2016, 10, 12.	2.9	51
115	Current and Future Treatment of Helicobacter pylori Infections. Advances in Experimental Medicine and Biology, 2019, 1149, 211-225.	1.6	51
116	Is There a Benefit to Extending the Duration of Helicobacter pylori Sequential Therapy to 14 Days?. Helicobacter, 2011, 16, 146-152.	3.5	50
117	Greater Than 95% Success with 14â€day <scp>B</scp>ismuth Quadruple Antiâ€<scp>H</scp>elicobacter pylori Therapy: A Pilot Study in <scp>US H</scp>ispanics. Helicobacter, 2012, 17, 382-390.	3.5	48
118	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients, 2019, 11, 613.	4.1	48
119	Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1997, 11, 529-532.	3.7	47
120	The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Review of Gastroenterology and Hepatology, 2019, 13, 17-24.	3.0	47
121	Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics, 2020, 9, 671.	3.7	47
122	Vonoprazanâ€containingHelicobacter pyloritriple therapies contribution to global antimicrobial resistance. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1159-1163.	2.8	47
123	Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Internal and Emergency Medicine, 2014, 9, 649-654.	2.0	45
124	Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Digestive Diseases and Sciences, 2016, 61, 3215-3220.	2.3	45
125	Hpâ€normogram (normoâ€graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and <scp>CYP</scp>2C19 Genotype. Helicobacter, 2016, 21, 85-90.	3.5	44
126	The Best Gastric Site for Obtaining a Positive Rapid Urease Test. Helicobacter, 1996, 1, 256-259.	3.5	43

#	Article	IF	Citations
127	Review article: urease, gastric ammonium/ammonia, and Helicobacter pylori â€" the past, the present, and recommendations for future research. Alimentary Pharmacology and Therapeutics, 1992, 6, 659-669.	3.7	43
128	Highâ€Dose Extendedâ€Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for <scp>H</scp>elicobacter pylori Infections. Helicobacter, 2014, 19, 319-322.	3.5	43
129	Evidence-based recommendations for successfulHelicobacter pyloritreatment. Expert Review of Gastroenterology and Hepatology, 2014, 8, 21-28.	3.0	43
130	Effects of aspirin and Helicobacter pylori on the gastroduodenal mucosal permeability to sucrose.. Gut, 1996, 39, 159-163.	12.1	41
131	Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the <scp>PRECISION</scp> trial. Alimentary Pharmacology and Therapeutics, 2018, 47, 1453-1463.	3.7	41
132	Immunoprotective oral whole cell vaccine for enterotoxigenicEscherichia colidiarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. FEMS Microbiology Letters, 1988, 47, 9-18.	1.8	40
133	Clinical Manifestations of Helicobacter pyloriâ€"Negative Gastritis. Clinical Gastroenterology and Hepatology, 2017, 15, 1037-1046.e3.	4.4	40
134	Genome and Methylome Variation in Helicobacter pylori With a cag Pathogenicity Island During Early Stages of Human Infection. Gastroenterology, 2018, 154, 612-623.e7.	1.3	40
135	Salvage Therapy after Two or More Prior Helicobacter pylori Treatment Failures: the Super Salvage Regimen. Helicobacter, 2003, 8, 307-309.	3.5	39
136	Autoimmune gastritis: long-term natural history in naÃ¯veHelicobacter pylori-negative patients. Gut, 2023, 72, 30-38.	12.1	39
137	Decrease in Gastric Permeability to Sucrose Following Cure of Helicobacter pylori Infection. Helicobacter, 1997, 2, 44-47.	3.5	38
138	Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology, 2021, 161, 1433-1442.e2.	1.3	38
139	Effect ofH. pyloriInfection and CagA Status on Leukocyte Counts and Liver Function Tests: Extraâ€Gastric Manifestations ofH. pyloriInfection. Helicobacter, 1998, 3, 174-178.	3.5	37
140	Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. American Journal of Gastroenterology, 2022, 117, 524-528.	0.4	36
141	Epidemiology of Campylobacter pylori infection. Gastroenterologie Clinique Et Biologique, 1989, 13, 84B-88B.	0.9	36
142	Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen,ÂorÂIbuprofen. Journal of the American College of Cardiology, 2018, 71, 1741-1751.	2.8	35
143	The Clinical Relevance of Manometric Esophagogastric Junction Outflow Obstruction Can Be Determined Using Rapid Drink Challenge and Solid Swallows. American Journal of Gastroenterology, 2021, 116, 280-288.	0.4	35
144	Risk Factors for Barrettâ€™s Esophagus Compared Between African Americans and Non-Hispanic Whites. American Journal of Gastroenterology, 2014, 109, 1870-1880.	0.4	34

#	Article	IF	Citations
145	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 537-546.	5.6	33
146	Experimental Human Infection with Norwalk Virus Elicits a Surrogate Neutralizing Antibody Response with Cross-Genogroup Activity. Vaccine Journal, 2015, 22, 221-228.	3.1	32
147	High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	31
148	Clarithromycinâ€amoxycillin therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1994, 8, 453-456.	3.7	30
149	Adherence, Internalization, and Persistence of Helicobacter pylori in Hepatocytes. Digestive Diseases and Sciences, 2008, 53, 2541-2549.	2.3	30
150	Barrett's Esophagus Suspected at Endoscopy but No Specialized Intestinal Metaplasia on Biopsy, What's Next?. American Journal of Gastroenterology, 2014, 109, 178-182.	0.4	30
151	Metachronous gastric cancer after successfulHelicobacter pylorieradication. World Journal of Gastroenterology, 2014, 20, 11552.	3.3	30
152	Critical Effect of Helicobacter pylori Infection on the Effectiveness of Omeprazole for Prevention of Gastric or Duodenal Ulcers Among Chronic NSAID Users. Helicobacter, 2002, 7, 1-8.	3.5	29
153	Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagnostic Microbiology and Infectious Disease, 2015, 81, 251-255.	1.8	29
154	Illusions regardingHelicobacter pyloriclinical trials and treatment guidelines. Gut, 2017, 66, 2043-2046.	12.1	29
155	Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Digestive Diseases and Sciences, 2017, 62, 1890-1896.	2.3	29
156	Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. American Journal of Gastroenterology, 1994, 89, 1203-5.	0.4	29
157	Short report: a nonâ€metronidazole triple therapy for eradication of Helicobacter pylori infectionâ€“tetracycline, amoxicillin, bismuth. Alimentary Pharmacology and Therapeutics, 1993, 7, 111-114.	3.7	28
158	Diagnosis. Current Opinion in Gastroenterology, 2019, 35, 535-543.	2.3	28
159	Helicobacter pyloridiagnosis and therapy in the era of antimicrobial stewardship. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110640.	3.2	28
160	Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett's esophagus in Nothern Sardinia. Scandinavian Journal of Gastroenterology, 2016, 51, 1281-1287.	1.5	27
161	Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987492.	3.2	27
162	How Do Practicing Clinicians Manage Helicobacter pyloriâ€Related Gastrointestinal Diseases in Germany? A Survey of Gastroenterologists and Family Practitioners. Helicobacter, 1998, 3, 1-8.	3.5	26

#	Article	IF	Citations
163	The Effect of galE Gene Inactivation on Lipopolysaccharide Profile of Helicobacter pylori. Current Microbiology, 1998, 37, 144-148.	2.2	26
164	Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut, 2017, 66, 384.2-386.	12.1	26
165	Achalasia diagnosed despite normal integrated relaxation pressure responds favorably to therapy. Neurogastroenterology and Motility, 2019, 31, e13586.	3.0	26
166	National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial. Gastroenterology, 2021, 161, 342-344.e1.	1.3	26
167	Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut, 2022, 71, 643-650.	12.1	26
168	Comparable Results of Helicobacter pylori Antibiotic Resistance Testing of Stools vs Gastric Biopsies Using Next-Generation Sequencing. Gastroenterology, 2022, 162, 2095-2097.e2.	1.3	26
169	Helicobacter pylori Therapy Demystified. Helicobacter, 2011, 16, 343-345.	3.5	25
170	Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. Journal of Digestive Diseases, 2012, 13, 54-59.	1.5	25
171	Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (GastrusÂ®) and a Proton-Pump Inhibitor. Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 2019, 1-8.	1.9	25
172	Prevention of Diarrhea Caused by Enterotoxigenic Escherichia coli: Lessons Learned with Volunteers. Clinical Infectious Diseases, 1990, 12, S68-S72.	5.8	24
173	Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic Sardinian patients. Internal and Emergency Medicine, 2015, 10, 787-794.	2.0	23
174	Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Digestive and Liver Disease, 2004, 36, 384-387.	0.9	23
175	DNA Fingerprinting of Single Colonies of Helicobacter pylori from Gastric Cancer Patients Suggests Infection with a Single Predominant Strain. Journal of Clinical Microbiology, 1999, 37, 245-247.	3.9	23
176	Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. Digestive Diseases and Sciences, 1992, 37, 1820-1824.	2.3	22
177	Helicobacter pylori Infection. New England Journal of Medicine, 2019, 381, 587-589.	27.0	22
178	Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 370.	1.1	22
179	Detection of Mycobacterium avium Complex in Cerebrospinal Fluid of a Sarcoid Patient by Specific Polymerase Chain Reaction Assays. Scandinavian Journal of Infectious Diseases, 1997, 29, 202-204.	1.5	21
180	Practical Rapid, Minimally Invasive, Reliable Nonendoscopic Method to Obtain Helicobacter pylori for Culture. Helicobacter, 2005, 10, 1-3.	3.5	21

#	Article	IF	Citations
181	Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Digestive Endoscopy, 2020, 32, 96-105.	2.3	21
182	Gastric endoscopy in the 21st century: Appropriate use of an invasive procedure in the era of non-invasive testing. Digestive and Liver Disease, 2008, 40, 497-503.	0.9	20
183	Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer-related bleeding: multicenter international registry. Endoscopy, 2021, 53, 36-43.	1.8	20
184	European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut, 2021, 70, 1-2.	12.1	20
185	Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?. Saudi Journal of Gastroenterology, 2017, 23, 265.	1.1	20
186	Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. American Journal of Gastroenterology, 1991, 86, 1158-62.	0.4	20
187	Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointestinal Endoscopy, 2019, 90, 457-460.	1.0	19
188	Habitual Sleep Duration and the Colonic Mucosa-Associated Gut Microbiota in Humansâ€”A Pilot Study. Clocks & Sleep, 2021, 3, 387-397.	2.0	19
189	Scope and consequences of peptic ulcer disease. Postgraduate Medicine, 1999, 105, 100-110.	2.0	18
190	Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Alimentary Pharmacology and Therapeutics, 2005, 21, 165-168.	3.7	18
191	Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6â€ƒweeks: A pilot study. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 59-61.	2.8	18
192	Alcohol use alters the colonic mucosaâ€“associated gut microbiota in humans. Nutrition Research, 2020, 83, 119-128.	2.9	18
193	Antimony electrodes. Digestive Diseases and Sciences, 1990, 35, 950-955.	2.3	17
194	Editorial â€“ Avoiding Unethical <scp>H</scp>elicobacter pylori Clinical Trials: Susceptibilityâ€Based Studies and Probiotics as Adjuvants. Helicobacter, 2015, 20, 321-325.	3.5	17
195	The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. F1000Research, 2018, 7, 715.	1.6	17
196	Twiceâ€‰â€‰day PPI, tetracycline, metronidazole quadruple therapy with PyleraÂ® or L a ctobacillus reuteri for treatment naÃ¯ve or for retreatment of Helicobacter pylori . Two randomized pilot studies. Helicobacter, 2019, 24, e12659.	3.5	17
197	Molecular-based Helicobacter pylori Susceptibility Testing Is Almost Ready for Prime Time. Gastroenterology, 2021, 160, 1936-1937.	1.3	17
198	Epidemiology of Campylobacter pylori infection: ethnic considerations. Scandinavian Journal of Gastroenterology, Supplement, 1988, 142, 9-13.	0.0	17

#	Article	IF	Citations
199	Perturbations in Gastric Physiology in Helicobacter pylori Duodenal Ulcer: Are They All Epiphenomena?. Helicobacter, 1997, 2, 44-49.	3.5	16
200	Effect of different organic acids (citric, malic and ascorbic) on intragastric urease activity. Alimentary Pharmacology and Therapeutics, 2005, 21, 1145-1148.	3.7	16
201	14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Digestive Diseases and Sciences, 2020, 65, 3639-3646.	2.3	16
202	Short Report: omeprazoleâ€tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1994, 8, 259-262.	3.7	15
203	Changes of tight junction and interleukinâ€8 expression using a human gastroid monolayer model ofHelicobacter pyloriinfection. Helicobacter, 2019, 24, e12583.	3.5	15
204	Immunology and Immunopathology of the Intestines: Molecular Biology and Immunology of Rotavirus Infections. Immunological Investigations, 1989, 18, 571-581.	2.0	14
205	Coâ€Existing Gastric Cancer and Duodenal Ulcer Disease: Role ofHelicobactor pyloriInfection. Helicobacter, 1997, 2, 205-209.	3.5	14
206	Rofecoxib and Clinically Significant Upper and Lower Gastrointestinal Events Revisited Based on Documents From Recent Litigation. American Journal of the Medical Sciences, 2011, 342, 356-364.	1.1	14
207	Optimizing first line 7â€day standard triple therapy forHelicobacter pylorieradication: Prolonging treatment or adding bismuth: which is better?. Journal of Digestive Diseases, 2018, 19, 674-677.	1.5	14
208	Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics, 2020, 9, 685.	3.7	14
209	Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR. PLoS ONE, 2014, 9, e83999.	2.5	14
210	Proinflammatory activation of neutrophils and monocytes by Helicobacter pylori is not associated with cagA, vacA or picB genotypes. Apmis, 1999, 107, 1117-1123.	2.0	13
211	Risk stratification for gastric cancer after Helicobacter pylori eradication: A populationâ€based study on Matsu Islands. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 671-679.	2.8	13
212	Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain. Advances in Experimental Medicine and Biology, 2019, 1148, 323-343.	1.6	13
213	Recent Developments Pertaining to H. pylori Infection. American Journal of Gastroenterology, 2021, 116, 1-3.	0.4	13
214	Rotaviruses code for two types of glycoprotein precursors. Journal of Cellular Biochemistry, 1983, 22, 151-160.	2.6	12
215	Is Antrum or Corpus the Best Site for Culture of Helicobacter pylori?. Helicobacter, 1996, 1, 88-91.	3.5	12
216	An Investigation into the Recent Increase in Gastric Cancer in the USA. Digestive Diseases and Sciences, 2018, 63, 1613-1619.	2.3	12

#	Article	IF	Citations
217	Roadmap for elimination of gastric cancer in Korea. Korean Journal of Internal Medicine, 2015, 30, 133.	1.7	12
218	Omeprazole as an adjuvant to antimicrobial therapy for eradication of Helicobacter pylori infection. Current Therapeutic Research, 1994, 55, 213-219.	1.2	11
219	NSAID ulcers: prevalence and prevention. Modern Rheumatology, 2000, 10, 2-7.	1.8	11
220	Stable Amoxicillin Resistance in Helicobacter pylori. Helicobacter, 2001, 6, 79-79.	3.5	11
221	Are there susceptible hosts to Helicobacter pylori infection?. Scandinavian Journal of Gastroenterology, Supplement, 1994, 205, 6-10.	0.0	11
222	Biotin-Avidin Amplified Elisa for Quantitation of Human IgA. Journal of Immunoassay, 1985, 6, 67-77.	0.3	10
223	The use of gastric salvage cytology in the diagnosis of malignancy: A review of 731 cases. Diagnostic Cytopathology, 1990, 6, 1-4.	1.0	10
224	InvasiveHelicobacterâ€Like Organisms in Feline Gastric Mucosa. Helicobacter, 1997, 2, 40-43.	3.5	10
225	Community acquired acuteHelicobacter pylorigastritis. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1353-1355.	2.8	10
226	OLGA Can Guard the Barn. American Journal of Gastroenterology, 2009, 104, 3099.	0.4	10
227	Hemostatic powder TCâ€325 treatment of malignancyâ€related upper gastrointestinal bleeds: International registry outcomes. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3027-3032.	2.8	10
228	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microbial Ecology, 2021, , 1.	2.8	10
229	Modern approach to the diagnosis of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2022, 55, S14-S21.	3.7	10
230	An Alternative Nonâ€Macrolide, Nonâ€Imidazole Treatment Regimen for CuringHelicobacter pyloriand Duodenal Ulcers: Ranitidine Bismuth Citrate Plus Amoxicillin. Helicobacter, 1998, 3, 125-131.	3.5	9
231	Practical advice on eradicatingHelicobacter pyloriinfection. Postgraduate Medicine, 1999, 105, 137-148.	2.0	9
232	Comparison of two multiband mucosectomy devices for endoscopic resection of Barrettâ€™s esophagus-related neoplasia. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 3665-3672.	2.4	9
233	Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia. United European Gastroenterology Journal, 2019, 7, 217-224.	3.8	9
234	A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrettâ€™s oesophagus in the United Kingdom. Current Medical Research and Opinion, 2019, 35, 805-815.	1.9	9

#	Article	IF	Citations
235	Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging. Gut, 2020, 69, 1151-1152.	12.1	9
236	Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter, 2021, 26, e12801.	3.5	9
237	Markers of Infection. , 0, , 499-510.		9
238	Campylobacter pylori as a Pathogenetic Factor in Duodenal Ulcer: the Case for. Scandinavian Journal of Gastroenterology, 1989, 24, 46-52.	1.5	8
239	Etest for Metronidazole Susceptibility in H. pylori: Use of the Wrong Standard May Have Led to the Wrong Conclusion. American Journal of Gastroenterology, 2004, 99, 769-769.	0.4	8
240	Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterology, 2017, 63, 77-79.	0.5	8
241	Enzyme therapy for functional bowel diseaseâ€like postâ€prandial distress. Journal of Digestive Diseases, 2018, 19, 650-656.	1.5	8
242	Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience. World Journal of Gastroenterology, 2018, 24, 4698-4707.	3.3	8
243	Managing bleeding risk after cold snare polypectomy in patients receiving direct-acting oral anticoagulants. Gastrointestinal Endoscopy, 2022, 95, 969-974.	1.0	8
244	Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. Gastroenterology, 1992, 102, 1289-94.	1.3	8
245	Helicobacter pylori Infection, Gastritis, and the Temperature of Choice for Hot Drinks. Helicobacter, 1996, 1, 172-174.	3.5	7
246	Development of a Murine Model ofHelicobacter pyloriInfection. Helicobacter, 1997, 2, 78-81.	3.5	7
247	Recognizing peptic ulcer disease. Postgraduate Medicine, 1999, 105, 113-133.	2.0	7
248	Monitoring the premalignant potential of Barrett's oesophagus'. Frontline Gastroenterology, 2016, 7, 316-322.	1.8	7
249	Spicy food and the stomach. Evaluation by videoendoscopy. JAMA - Journal of the American Medical Association, 1988, 260, 3473-5.	7.4	7
250	Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptibleHelicobacter pyloriinfection. Alimentary Pharmacology and Therapeutics, 1999, 13, 169-172.	3.7	6
251	Pathogenesis of increased sucrose permeability in H. pylori gastritis. , 2000, 45, 889-889.		6
252	Editorial: HelicobacterÂpylori and gastric cancer in Alaskan Natives: Time to stop studying H.Âpylori and to eradicate it. Helicobacter, 2018, 23, e12478.	3.5	6

#	Article	IF	Citations
253	High-flow nasal cannula oxygen therapy obscures severe respiration depression, providing an illusion of safety. Gastrointestinal Endoscopy, 2020, 91, 720-721.	1.0	6
254	It is Time to Rethink H. pylori Therapy. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 115-117.	0.9	6
255	Campylobacter pylori. The organism and its clinical relevance. Journal of Clinical Gastroenterology, 1989, 11 Suppl 1, S43-8.	2.2	6
256	Classification system forHelicobacter pyloritherapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter, 2021, 26, e12773.	3.5	5
257	Screening for Gastric Cancer: Focus on the Ants Instead of the Ant Hill. Clinical Gastroenterology and Hepatology, 2021, 19, 1990-1991.	4.4	5
258	Bisphosphonate gastrointestinal damage: perspective and research needs. Pharmacoepidemiology and Drug Safety, 2000, 9, 377-381.	1.9	4
259	Diagnostics for Statistical Variable Selection Methods for Prediction of Peptic Ulcer Disease in Helicobacter pylori Infection. Journal of Proteomics and Bioinformatics, 2014, 07, 1000307.	0.4	4
260	Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ Evidence-Based Medicine, 2018, 23, 111-112.	3.5	4
261	No Barrettâ€™sâ€”No Cancer. Journal of Clinical Gastroenterology, 2020, 54, 136-143.	2.2	4
262	NSAID ulcers: prevalence and prevention. Modern Rheumatology, 2000, 10, 2-7.	1.8	4
263	Helicobacter pylori infection in Japan: current status and future options. European Journal of Gastroenterology and Hepatology, 1994, 6 Suppl 1, S1-4.	1.6	4
264	Treatment of Steatorrhea in Chronic Pancreatitis. Hospital Practice (1995), 1986, 21, 125-129.	1.0	3
265	Antimony electrodes forin vivo pH monitoring. Digestive Diseases and Sciences, 1991, 36, 1180-1181.	2.3	3
266	Costs of Managing Helicobacter pylori-Infected Ulcer Patients after Initial Therapy. Helicobacter, 2001, 6, 66-76.	3.5	3
267	Helicobacter pylori: New Thoughts and Practices. Gastroenterology Clinics of North America, 2015, 44, xv-xvi.	2.2	3
268	Brief report: Lactobacillus bulgaricus <scp>GLB</scp>44 (Proviotic^{â„¢}) plus esomeprazole for Helicobacter pylori eradication: A pilot study. Helicobacter, 2018, 23, e12476.	3.5	3
269	Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study. BMJ Open, 2019, 9, e032013.	1.9	3
270	Rofecoxib and Clinically Significant Gastrointestinal Events: Response. American Journal of the Medical Sciences, 2019, 358, e9-e10.	1.1	3

#	Article	IF	Citations
271	Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything?. Digestive Diseases and Sciences, 2019, 64, 4-6.	2.3	3
272	Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy. Endoscopy International Open, 2020, 08, E891-E899.	1.8	3
273	Radiofrequency ablation for Barrettâ€™s oesophagus related neoplasia with the 360 Express catheter: initial experience from the United Kingdom and Irelandâ€”preliminary results. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 598-606.	2.4	3
274	Synopsis of Antibiotic Treatment. , 2016, , 417-426.		3
275	Should I search for Campylobacter pylori in my patients? Much ado about not much?. American Journal of Gastroenterology, 1988, 83, 481-3.	0.4	3
276	Helicobacter 2006: A Note from the Editor. Helicobacter, 2006, 11, 1-1.	3.5	2
277	Reply to Kirby et al. Journal of Infectious Diseases, 2015, 211, 167-167.	4.0	2
278	952 Active Gastric Inflammation in Human Volunteers After Exposure to a Cag-Positive H. pylori Challenge in a Placebo Controlled Vaccine Trial. Gastroenterology, 2016, 150, S188.	1.3	2
279	Acute Pancreatitis With Long-Term Celecoxib VS. Ibuprofen or Naproxen: Data From the PRECISION Trial. American Journal of Gastroenterology, 2018, 113, 1053-1054.	0.4	2
280	Empiric H. pylori therapyâ€”10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best. Translational Cancer Research, 2016, 5, S1476-S1478.	1.0	2
281	It Should Be Possible to Eliminate Peptic Ulcer Disease and Gastric Carcinoma from Saudi Arabia. Annals of Saudi Medicine, 1994, 14, 179-182.	1.1	2
282	Chairman's introduction. Helicobacter, 2000, 5, 1-1.	3.5	2
283	Polymorphonuclear leukocytes traffic into the gastric mucosa and through the gastric mucosal barrier in H. pylori infection: is that bad?. , 1994, , 214-221.		1
284	Approach to the Patient with Dyspepsia and Peptic Ulcer Disease. , 0, , 99-121.		1
285	Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis. Alimentary Pharmacology and Therapeutics, 2017, 46, 1117-1118.	3.7	1
286	Editorial: recurrence of Helicobacter pylori infectionâ€”still the same after all these yearsâ€¦ Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 132-133.	3.7	1
287	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 2005-2006.	4.4	1
288	The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy. Current Medical Research and Opinion, 2020, 36, 977-983.	1.9	1

#	Article	IF	Citations
289	Mechanical colon cleansing for screening colonoscopy: A randomized controlled trial. Journal of Digestive Diseases, 2017, 18, 691-697.	1.5	1
290	Comments regarding use of rifabutin for Helicobacter pylori eradication. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110440.	3.2	1
291	Helicobacter pylori, the bacterial cause of peptic ulcers and its potential impact on dental workers. The Journal of the Greater Houston Dental Society, 1991, 63, 3-4.	0.1	1
292	Survival analysis of variceal hemorrhage. Hepatology, 1988, 8, 978-978.	7.3	0
293	Mycobacteria, infant goats, and Crohn's disease. Digestive Diseases and Sciences, 1988, 33, 251-251.	2.3	0
294	It is not all black and white: Future incidence of stomach cancer will be substantially higher than projected due to the effects of immigration and increasing Hispanic and Asian populations in the United States. Cancer, 2015, 121, 4266-4267.	4.1	0
295	Gastritis and Gastropathy. , 2016, , 140-148.		0
296	Reply. Gastroenterology, 2016, 151, 774-775.	1.3	0
297	ADTH-07â€…Deep learning based classification of intrapapillary capillary loops for detection of early oesophageal squamous neoplasia. , 2018, , .		0
298	PWE-132â€…Therapeutic outcomes following endotherapy for refractory gastroparesis. , 2018, , .		0
299	PTH-069â€…Validating a classification system using ISCAN optical enhancement for detection of early barrettâ€™s oesophagus neoplasia. , 2018, , .		0
300	OWE-004â€…Iscan OE improves detection of early barretts oesophagus associated neoplasia in trainee and expert endoscopists. , 2018, , .		0
301	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 2004.	4.4	0
302	Editorial: gastrointestinal safety of <scp>COX</scp>â€2 selective and nonselective <scp>NSAID</scp>sâ€”the impact of the <scp>PRECISION</scp> trial. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1546-1547.	3.7	0
303	Editorial: not yet time for universal susceptibilityâ€guided firstâ€line Helicobacter pylori treatmentâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 332-332.	3.7	0
304	PTU-051â€…Risk factors for progression of confirmed low grade dysplasia in a barrettâ€™s tertiary referral centre. , 2019, , .		0
305	PTU-052â€…The natural history of low-grade dysplasia in patients with barrettâ€™s oesophagus: a tertiary centre experience. , 2019, , .		0
306	Stress Ulcer Prophylaxis for ICU Patients. JAMA - Journal of the American Medical Association, 2020, 324, 101.	7.4	0

#	Article	IF	Citations
307	P31â€…Hemospray in the treatment of variceal bleeds: outcomes from the international hemospray registry. , 2021, , .		0
308	P32â€…Use of Hemospray in the treatment of lower gastrointestinal bleeds: outcomes from the hemospray registry. , 2021, , .		0
309	Things We Do for No Reasonâ„¢: Serum Serologic Helicobacter pylori Testing. Journal of Hospital Medicine, 2021, 16, 691-693.	1.4	0
310	P33â€…Hemospray treatment in non-variceal Upper Gastrointestinal bleeds: outcomes from the first 500 Hemospray registry patients. , 2021, , .		0
311	PTU-55â€…Biliary stone characteristics determining difficulty at conventional ERCP and need for cholangioscopy-assisted lithotripsy. , 2021, , .		0
312	IDDF2020-ABS-0163â€…Reduced survival post-endoscopy for upper gastrointestinal bleeding in the COVID-19 era is a secondary effect of the response to the global pandemic. , 2020, , .		0
313	Helicobacter pylori. Current Topics in Microbiology and Immunology, 2021, , .	1.1	0
314	Gastroenterology today and tomorrow. American Journal of Gastroenterology, 1992, 87, 559-61.	0.4	0
315	Gastritis and Gastropathy. , 0, , 251-260.		0